|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||44.57 - 45.97|
|52 Week Range||42.62 - 88.80|
|PE Ratio (TTM)||-58.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
DexCom, Inc. (NASDAQ: DXCM ) shares got hammered Sept. 28 when rival Abbott Laboratories (NYSE: ABT ) received FDA approval for its FreeStyle Libre flash glucose monitoring system. Investors see Abbott’s ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DexCom, Inc. Here are 5 ETFs with the largest exposure to DXCM-US. Comparing the performance and risk of DexCom, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis DexCom, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of DexCom, Inc. – MGC Diagnostics Corporation and Medtronic plc (MGCD-US and MDT-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 170.60 million, Net Earnings ... Read more (Read more...)
DXCM stock fell following ABT's announcement, while ABT’s stock price rose. The Vanguard Dividend Appreciation ETF (VIG) rose that day as well.
Stocks that moved substantially or traded heavily Thursday: Abbott Laboratories, up $1.49 to $53.64 Regulators approved Abbott's new blood glucose monitoring system. Hain Celestial Group Inc., up 28 cents ...
The FDA on Wednesday approved a device that monitors blood sugar levels without needing to...
Shares of DexCom are down more than 35% Thursday after Abbott Labs secured FDA approval for its new glucose monitoring system. Jim Cramer calls Abbott Labs a buy.
Despite a more than 35 percent plunge in DexCom, Inc. (NASDAQ: DXCM )'s stock, analysts at Canaccord Genuity continue to hold a bullish outlook. The firm's Kyle Rose maintains a Buy on DexCom's stock with ...
The Food and Drug Administration approved Abbott's FreeStyle Libre glucose monitoring system.
Today, shares of DexCom (DXCM) has plunged 36% to just over $43 after Abbott Laboratories (ABT) received FDA approval for a blood sugar-monitoring system for diabetics that doesn't require a finger prick. Abbott plans to sell it at retail pharmacies, and pursue the all-important Medicare reimbursement As one might expect, Abbott’s stock price climbed 4.1% to $54.32 a share, given that it’s a big potential upside to the company’s diabetes care franchise. As Joanne Wuensch at BMO Capital Markets writes: On the commercial side we expect significant patient demand: For example, in Europe, which includes full reimbursement in France and in the U.K., and over 400,000 patients there use the Libre.
The U.S. Food and Drug Administration said it approved Abbott Laboratories' glucose monitoring device for adults with diabetes, allowing millions of people to track their blood sugar levels without having to prick their fingers. Abbott's FreeStyle Libre Flash reduces the need for fingerstick testing, which is painful and inconvenient, by inserting a small sensor wire below the skin to continuously measure and monitor glucose levels. Chicago-based Abbott's shares were trading up 3.6 percent at $54 after the bell on Wednesday.
The U.S. Food and Drug Administration on Wednesday approved Abbott Laboratories' glucose monitoring device for adults with diabetes, allowing millions of people to track their blood sugar levels without having to prick their fingers. Abbott's FreeStyle Libre Flash reduces the need for fingerstick testing, which is painful and inconvenient, by using a small sensor wire that is inserted below the skin to continuously measure and monitor glucose levels. Chicago-based Abbott's shares were trading up about 2 percent at $53.25 after the bell on Wednesday.
FIT stock also should benefit from year-over-year comparisons. According to various reviews, it appears that the device is having issues with its cellular features, such as connection with LTE networks as well as problems with the draining of the battery.
Fitbit Inc (NYSE:FIT) stock has finally broken out. Fitbit stock traded mostly between $5 and $6 after plunging. InvestorPlace columnist Larry Ramer argued the product would give a boost to FIT stock, and he may be right.
Fitbit Inc (NYSE:FIT) got a nice boost when it finally announced its Ionic smartwatch at the end of August. With the ability to see their blood glucose levels on their wrist, in real time, the new Fitbit smartwatch will go beyond fitness to offer people suffering from diabetes a real reason to buy. Last week, Fitbit announced it was partnering with Dexcom, the leading manufacturing of continuous glucose monitoring (CGM) devices.